Format

Send to

Choose Destination
Am J Psychiatry. 2015 Mar 1;172(3):237-48. doi: 10.1176/appi.ajp.2014.13101355. Epub 2014 Dec 4.

Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study.

Author information

1
From the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; the Departments of Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, N.Y.; Psychiatry Research, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, N.Y.; SUNY Downstate Medical Center, New York; Albert Einstein College of Medicine, Bronx, N.Y.; Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Canada; Geisel School of Medicine, Dartmouth, N.H.; the Departments of Social Medicine and Psychology, University of North Carolina, Chapel Hill; the Center for Psychiatric Rehabilitation, Departments of Occupational Therapy, Psychiatry, and Psychology, Boston University, Boston; the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, N.Y.; the Department of Psychiatry and Adolescent and Child Psychiatry, New York University Langone Medical Center, New York; the Departments of Psychiatry and Epidemiology and Public Health, Yale School of Medicine, New Haven, Conn.; and NIMH, Bethesda, Md.

Abstract

OBJECTIVE:

Treatment guidelines suggest distinctive medication strategies for first-episode and multiepisode patients with schizophrenia. To assess the extent to which community clinicians adjust their usual treatment regimens for first-episode patients, the authors examined prescription patterns and factors associated with prescription choice in a national cohort of early-phase patients.

METHOD:

Prescription data at study entry were obtained from 404 participants in the Recovery After an Initial Schizophrenia Episode Project's Early Treatment Program (RAISE-ETP), a nationwide multisite effectiveness study for patients with first-episode schizophrenia spectrum disorders. Treatment with antipsychotics did not exceed 6 months at study entry.

RESULTS:

The authors identified 159 patients (39.4% of the sample) who might benefit from changes in their psychotropic prescriptions. Of these, 8.8% received prescriptions for recommended antipsychotics at higher than recommended dosages; 32.1% received prescriptions for olanzapine (often at high dosages), 23.3% for more than one antipsychotic, 36.5% for an antipsychotic and also an antidepressant without a clear indication, 10.1% for psychotropic medications without an antipsychotic, and 1.2% for stimulants. Multivariate analysis showed evidence for sex, age, and insurance status effects on prescription practices. Racial and ethnic effects consistent with effects reported in previous studies of multiepisode patients were found in univariate analyses. Despite some regional variations in prescription practices, no region consistently had different practices from the others. Diagnosis had limited and inconsistent effects.

CONCLUSIONS:

Besides prescriber education, policy makers may need to consider not only patient factors but also service delivery factors in efforts to improve prescription practices for first-episode schizophrenia patients.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01321177.

PMID:
25727536
PMCID:
PMC4358323
DOI:
10.1176/appi.ajp.2014.13101355
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center